Skip to ContentSkip to Navigation
Practical matters How to find us dr. T. van Meerten

Publications

Antibody Response in Immunocompromised Patients with Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma

CD47-SIRPĪ± blocking-based immunotherapy: Current and prospective therapeutic strategies

DSP107 combines inhibition of CD47/SIRPĪ± axis with activation of 4-1BB to trigger anticancer immunity

High frequency of hyperglycaemia observed during CAR T-cell treatment

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL Registry

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma

Read more

Press/media

Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

Dit was 2021: Genezen

UMCG gaat zelf medicijn tegen lymfeklierkanker maken

Podcast De Genezers over CAR T-celtherapie

Gronings ziekenhuis gaat prijzig kankermedicijn zelf maken met miljoenensubsidie

€ 30 miljoen subsidie voor UMCG-onderzoek naar veelbelovende kankerbehandeling

Wanneer milieuwetgeving de strijd tegen kanker hindert

Doorbraak in behandeling lymfeklierkanker

Read more